Systemic therapy for bladder cancer – a medical oncologist’s perspective
Open Access
- 13 February 2014
- journal article
- Published by Sciedu Press in Journal of Solid Tumors
- Vol. 4 (2), 25-35
- https://doi.org/10.5430/jst.v4n2p25
Abstract
Advanced bladder cancer, both muscle-invasive localized disease and metastatic disease, is managed with systemic chemotherapy. Cisplatin-based multi-agent chemotherapy remains the cornerstone for systemic therapy. MVAC (methotrexate-vinblastine-doxorubicin-cisplatin) has been most rigorously studied, both neoadjuvantly and for palliation of metastatic disease. For metastatic disease, cisplatin-gemcitabine (GC) has compared favorably to MVAC due to improved tolerability with similar efficacy. GC has been adopted as standard therapy. Neoadjuvant chemotherapy for muscle-invasive bladder cancer improves survival among those patients eligible to receive cisplatin. Adjuvant chemotherapy is difficult to administer effectively given morbidity of radical cystectomy, and studies have shown mixed results about its benefit. Non-cisplatin regimens have been investigated but remain experimental and reserved for those not candidates for cisplatin in the metastatic setting. While multiple agents have been studied after metastatic disease progression after cisplatin-based therapy, there remain no FDA-approved therapies for the second line. Future trials with anti-VEGF therapy and immunotherapy are actively being investigated. This review examines the systemic therapy available to oncologists with current evidence and future directions.Keywords
This publication has 70 references indexed in Scilit:
- Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: A phase II studyAsia-Pacific Journal of Clinical Oncology, 2012
- Inflammatory Pathways as Promising Targets to Increase Chemotherapy Response in Bladder CancerMediators of Inflammation, 2012
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987Journal of Clinical Oncology, 2012
- Sequential Therapy with Gemcitabine and Carboplatin Followed by Paclitaxel as First Line Treatment for Advanced Urothelial CancerJournal of Cancer, 2012
- International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 TrialJournal of Clinical Oncology, 2011
- Late Pelvic Toxicity After Bladder-Sparing Therapy in Patients With Invasive Bladder Cancer: RTOG 89-03, 95-06, 97-06, 99-06Journal of Clinical Oncology, 2009
- A Sequential Treatment Approach to Myoinvasive Urothelial Cancer: A Phase II Southwest Oncology Group Trial (S0219)Journal of Urology, 2009
- Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the BladderJournal of Urology, 2008
- Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802)Cancer, 2008
- Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumoursEuropean Journal Of Cancer, 2006